121 related articles for article (PubMed ID: 30732888)
1. Desferrioxamine-caffeine shows improved efficacy in chelating iron and depleting cancer stem cells.
Li B; Espósito BP; Wang S; Zhang J; Xu M; Zhang S; Zhang Z; Liu S
J Trace Elem Med Biol; 2019 Mar; 52():232-238. PubMed ID: 30732888
[TBL] [Abstract][Full Text] [Related]
2. Desferrioxamine-caffeine (DFCAF) as a cell permeant moderator of the oxidative stress caused by iron overload.
Alta EC; Goswami D; Machini MT; Silvestre DM; Nomura CS; Espósito BP
Biometals; 2014 Dec; 27(6):1351-60. PubMed ID: 25265871
[TBL] [Abstract][Full Text] [Related]
3. The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.
Wang L; Li X; Mu Y; Lu C; Tang S; Lu K; Qiu X; Wei A; Cheng Y; Wei W
J Trace Elem Med Biol; 2019 Dec; 56():131-138. PubMed ID: 31466045
[TBL] [Abstract][Full Text] [Related]
4. Desferrioxamine and desferrioxamine-caffeine as carriers of aluminum and gallium to microbes via the Trojan Horse Effect.
Huayhuaz JAA; Vitorino HA; Campos OS; Serrano SHP; Kaneko TM; Espósito BP
J Trace Elem Med Biol; 2017 May; 41():16-22. PubMed ID: 28347458
[TBL] [Abstract][Full Text] [Related]
5. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
Richardson D; Ponka P; Baker E
Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
[TBL] [Abstract][Full Text] [Related]
6. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
7. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
[TBL] [Abstract][Full Text] [Related]
8. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
[TBL] [Abstract][Full Text] [Related]
9. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
[TBL] [Abstract][Full Text] [Related]
10. Deferoxamine-induced increase in the intracellular iron levels in highly aggressive breast cancer cells leads to increased cell migration by enhancing TNF-α-dependent NF-κB signaling and TGF-β signaling.
Liu P; He K; Song H; Ma Z; Yin W; Xu LX
J Inorg Biochem; 2016 Jul; 160():40-8. PubMed ID: 27138103
[TBL] [Abstract][Full Text] [Related]
11. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
Hoyes KP; Porter JB
Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
[TBL] [Abstract][Full Text] [Related]
12. Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.
Kicic A; Chua AC; Baker E
Br J Pharmacol; 2002 Mar; 135(6):1393-402. PubMed ID: 11906952
[TBL] [Abstract][Full Text] [Related]
13. Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.
Maclean KH; Cleveland JL; Porter JB
Blood; 2001 Dec; 98(13):3831-9. PubMed ID: 11739193
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2.
Kuban-Jankowska A; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Wozniak M
Anticancer Res; 2017 Sep; 37(9):4799-4806. PubMed ID: 28870898
[TBL] [Abstract][Full Text] [Related]
15. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
16. Desferrioxamine enhances AIDS-associated Kaposi's sarcoma tumor development in a xenograft model.
Simonart T; Boelaert JR; Andrei G; van den Oord JJ; Degraef C; Hermans P; Noel JC; Van Vooren JP; Heenen M; De Clercq E; Snoeck R
Int J Cancer; 2002 Jul; 100(2):140-3. PubMed ID: 12115561
[TBL] [Abstract][Full Text] [Related]
17. Chelation of thallium by combining deferasirox and desferrioxamine in rats.
Saljooghi AS; Babaie M; Mendi FD; Zahmati M; Saljooghi ZS
Toxicol Ind Health; 2016 Jan; 32(1):83-8. PubMed ID: 24021432
[TBL] [Abstract][Full Text] [Related]
18. In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators.
Rossi NA; Mustafa I; Jackson JK; Burt HM; Horte SA; Scott MD; Kizhakkedathu JN
Biomaterials; 2009 Feb; 30(4):638-48. PubMed ID: 18977029
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
[TBL] [Abstract][Full Text] [Related]
20. Triphenylphosphonium-desferrioxamine as a candidate mitochondrial iron chelator.
Alta RYP; Vitorino HA; Goswami D; Terêsa Machini M; Espósito BP
Biometals; 2017 Oct; 30(5):709-718. PubMed ID: 28770399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
